CoChat

Design of the Reduction of Events with Darbepoetin Alfa in Heart Failure (RED-HF): A Phase III, Anaemia Correction, Morbidity–Mortality Trial

Open access
McMurray, John J.V., Anand, Inder S., Diaz, Rafael, Maggioni, Aldo P., O’Connor, Christopher, Pfeffer, Marc A., Polu, Krishna R., Solomon, Scott D., Sun, Yan, Swedberg, Karl, Tendera, Michal, van Veldhuisen, Dirk J., Wasserman, Scott M., Young, James B. · 2009 · European Journal of Heart Failure
Cited by 119

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background: Patients with heart failure (HF) and anaemia have greater functional impairment, worse symptoms, increased rates of hospital admission, and a higher risk of death, compared with non-anaemic HF patients. Whether correcting anaemia can improve outcomes is unknown. Objective: The Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF; Clinical Trials.gov NCT 003 58215) was designed to evaluate the effect of the long-acting erythropoietin-stimulating agent darbepoetin alfa on mortality and morbidity (and quality of life) in patients with HF and anaemia. Methods: Approximately 2600 patients with New York Heart Association class II–IV, an ejection fraction ≤40%, and a haemoglobin (Hb) consistently ≤12.0 g/dL but ≥9.0 g/dL will be enrolled. Patients are randomized 1:1 to double-blind subcutaneous administration of darbepoetin alfa or placebo. Investigators are also blinded to Hb measurements and darbepoetin alfa is dosed to achieve an Hb concentration of 13.0 g/dL (but not exceeding 14.5 g/dL) with sham adjustments of the dose of placebo. The primary endpoint is the time to death from any cause or first hospital admission for worsening HF, whichever occurs first. The study will complete when ~1150 subjects experience a primary endpoint.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurjhf/hfp098

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 119

Metadata

Authors
McMurray, J. J. V., Anand, I. S., Diaz, R., Maggioni, A. P., O’Connor, C., Pfeffer, M. A., Polu, K. R., Solomon, S. D., Sun, Y., Swedberg, K., Tendera, M., van Veldhuisen, D. J., Wasserman, S. M., & Young, J. B.
Venue
European Journal of Heart Failure
Published
2009-07-24
Volume
11
Issue
8
Pages
795-801
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2012944154
Cited by
119
References
2
FWCI
13.87
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design of the Reduction of Events with Darbepoetin Alfa in Heart Failure (RED-HF): A Phase III, Anaemia Correction, Morbidity–Mortality Trial. https://app.cochat.ai/papers/10.1093/eurjhf/hfp098
The paper
McMurray, J. J. V., Anand, I. S., Diaz, R., Maggioni, A. P., O’Connor, C., Pfeffer, M. A., Polu, K. R., Solomon, S. D., Sun, Y., Swedberg, K., Tendera, M., van Veldhuisen, D. J., Wasserman, S. M., & Young, J. B. (2009). Design of the Reduction of Events with Darbepoetin Alfa in Heart Failure (RED-HF): A Phase III, Anaemia Correction, Morbidity–Mortality Trial. European Journal of Heart Failure. https://doi.org/10.1093/eurjhf/hfp098

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.